1.
RESPONSE SCIENTIFIC, INC. (RSI)is a biotechnology company founded in May 2002. RSIs mission is to improve peoples livesthrough innovative research leading to revolutionary new healthcare treatments. 5 Independence Way – Suite 300 Princeton, New Jersey 08540 Contact Gregg Webster, CEO Tel 609-945-4913 gwebster@responsescientific.com ©2012 RSI

2.
RSI has assembled a stellar scientific advisory board and personnel to accomplish our mission and address the global health concerns of millions of people. Chairman: Emmanuel C. Opara, PhD. Wake Forest University Medical School Institute for Regenerative Medicine Winston-Salem, North Carolina©2012 RSI Page 2

3.
Response Scientific’s focus is twofold: 1) Introduce our patented insulin resistance treatment, Receptorex INS2*, prescription-only medical food to market. 2) Introduce our patented Aegis Fluidics Microencapsulation™ technology that protects and shields encapsulated drugs, nutraceuticals, Probiotics, and medical foods from damaging stomach acids and enzymatic degradation *Code Name©2012 RSI Page 3

4.
Type 1 and Type 2 Diabetes Discovery Insulin Resistance Treatment RSIs insulin resistance small molecule prescription medical food formulation Receptorex INS2* is comprised of liquid GRAS components which reduce ROS imbalance, thereby enhancing insulin sensitivity and lowering the amount of insulin required to maintain targeted blood glucose levels.*Code Name ©2012 RSI Page 4

5.
RSI plans to bring this patented prescription medical food to market in 1Q 2013. Receptorex INS2* has demonstrated the ability to repair or sensitize damaged insulin receptors and lower the amount of insulin required to maintain healthy blood glucose levels by up to 50%. Applies to both Type 1 and Type 2 Diabetes patients. Receptorex INS2* may also delay or even prevent Pre-Diabetes patients from advancing to full-blown diabetes. No prescription medication exists today that reduces the amount of exogenous insulin without increasing blood glucose levels.*Code Name©2012 RSI Page 5

6.
Receptorex INS2* may also benefit sufferers of Alzheimer’s disease and PCOS (polycystic ovarian syndrome) as insulin resistance directly affects both of these disease states. In 2006 researchers at Brown University coined the term Type 3 Diabetes after discovering the insulin resistance link to Alzheimers. PCOS is currently treated with Metformin, a diabetes medication. It is important to note that Receptorex INS2* will be the first medication to utilize our newly developed Aegis Fluidics™ Microencapsulation drug delivery technology.*Code Name©2012 RSI Page 6

7.
Wholly-Owned Subsidiary of Response Scientific, Inc. Aegis Fluidics™ is the sales and marketing arm of RSI’s patented microfluidics encapsulation device and technology. Hogan Lovells, our patent attorneys, advise that certain products manufactured utilizing our technology may qualify for new patents. Developed and Patented by North Carolina State University and Biocell Technologies Exclusive Worldwide Licensee: Response Scientific, Inc.©2012 RSI Page 7

8.
Bioavailability Breakthrough Superior Delivery To BloodstreamAegis Microfluidics capsules Deliver Contents ByDiffusion* The Aegis Microcapsules travel through the stomach to the small intestines virtually unharmed by stomach acids or enzymatic actions. Diffusion of the contents of the microcapsules begins upon entry to the small intestines and continues through the digestive tract releasing contents along the way. Approximately 60% of the contents are emptied in the first 60 minutes. Diffusion and Concentration Gradients The passage of the microcapsules through the intestines is dependent on the concentration gradients. A concentration gradient exists whenever a concentrated solution is in contact with a less concentrated solution. Because the solutions are in contact, particles may flow between the two solutions by the process known as diffusion. Diffusion is a term used to describe the mixing of two different substances that are placed in contact. Diffusion is the migrating of these different particles. Although particles move in every direction, there is a net flow from the more concentrated solution to the less concentrated solution. As the number of particles in the more concentrated solution diminishes and the number of particles in the less concentrated increases, the difference in concentration between the two solutions decreases. Hence, the concentration gradient is said to get smaller. All else being equal, the concentrations of the solutions change more rapidly when the difference in their concentrations is greater. This diffusion process continues until the concentrations of the two solutions are equal. This state is known as dynamic equilibrium. When the two solutions are in dynamic equilibrium, particles continue to move between the two solutions, but there is no net flow in any one direction. While in transit through the digestive tract the Aegis Fluidics Microcapsules never reach equilibrium and therefore continue to empty their contents until the contents are exhausted. * See drawing next page Page 8

9.
Page 9

10.
The patented Aegis Fluidics device allows for the mass production of Prescription Drugs, Prescription Medical Foods & Nutraceuticals. The resulting microcapsules are time-released, acid resistant, and not digestible by enzymes, thus shielding the components from both acid and enzymatic degradation.©2012 RSI Page 10

11.
Bioavailability is the amount of a drug that enters the bloodstream. Drugs are considered to have good or poor bioavailability. The Aegis Fluidics™ technology increases bioavailability allowing lower amounts of ingredients to produce the performance of higher amounts of ingredients. In light of the economies of scale, the cost savings to major manufacturers of drugs, nutraceuticals and medical foods are expected to be substantial.©2012 RSI Page 11

12.
Scalability The Aegis Fluidics™ device is easily scalable, from small testing or sample production to large mass production volumes for market. In 2012 RSI will begin to sublicense this technology to pharmaceutical manufacturers.©2012 RSI Page 12

13.
CANADIAN TEST MARKET The Canadian population is 31,280 million or 10% of the US 10% benchmark is used by Canadian companies wanting to do business in the US as an estimate of the total business potential. 75% of Canadians live in urban areas. Large urban areas in Canada are: Toronto, Montreal, Ottawa, Vancouver, Edmonton, Calgary, SW Ontario, and the province of Quebec. Canadian urban centers Toronto and Vancouver contain an ever growing Asian population. Asian countries hold tremendous potential. 90% of Canadians live within 100 miles of the US border and are familiar with US shopping habits, presenting a favorable advantage for marketing dollars. The eastern provinces of Nova Scotia, New Brunswick and Prince Edward Island are considered as having markets and cultures similar to the US.©2012 RSI Page 13

14.
CANADIAN TEST MARKET Retail Stores The total Canadian retail market in terms of dollars per year is $260 billion (multiply x 10 for the US). Drugs and medicine represent 13.3 billion dollars. Food sales (grocery stores) count for 59 billion. Supermarkets count for 55 billion in sales. Canadian retailers pay their bills within 30 days.©2012 RSI Page 14

15.
CANADIAN TEST MARKET Manufacturing The best location for a Canadian manufacturing facility is along the Ontario 401 highway corridor. The 401 runs from Windsor, Ontario (close to Detroit US) to Ottawa. The 401 is Canadas busiest highway. A manufacturing location located along the 401 corridor is essential in order to take advantage of the best distribution options available and service the highly populated area of southwestern Ontario. The head offices of most of Canadas retailers are located in Toronto. The US is Canadas largest trading partner and the Canadian dollar has been trading on par for the last few months and it is expected to do so for the next few years. This is an important factor for US companies doing business in Canada.©2012 RSI Page 15

16.
5 Independence Way – Suite 300, Princeton, New Jersey 08540 Contact Gregg Webster, CEO Tel 609-945-4913 gwebster@responsescientific.com